Search results
Order by most recent / most popular / relevance
Results: 1-10 of 114
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 1 2013
The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Health Canada has released a Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of
NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 6 2013
The PMPRB has announced a Monitoring and Evaluation Plan for the Major Changes in the Guidelines. CIPO has announced a new PCT-Patent Prosecution
Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits
Court dismisses NOC proceeding for mootness when NOA withdrawn
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to
Judicial review brought outside time period and no vested right to NOC
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This decision relates to the consideration by the Minister of Health of Apotex’ submission for a Notice of Compliance (NOC) for omeprazole magnesium
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 9 2013
Health Canada has announced a Consultation on the new Prescription Drug List. The consultation is open for comment until March 7, 2013. Health Canada has
Current Search
- Workarea - Patents
- Workarea - Healthcare
- Jurisdiction - Canada
- Author - Chantal Saunders